• New strategies are needed to inhibit thrombosis and intimal hyperplasia (IH) in vein grafts (VG).
Introduction
Approximately 400 000 coronary artery bypass graft (CABG) surgeries are performed annually in the USA. The saphenous vein is the most commonly used bypass graft. After CABG, vein grafts (VGs) undergo significant structural and functional changes, driven by differences in blood pressure and sheer stress between the venous and arterial circulations. Whereas some changes that occur in VGs represent adaptive responses, maladaptive responses are common and can lead to VG occlusion, which occurs in approximately 20% and 40% of VGs within 1 years and 10 years after surgery, respectively [1] . Early graft failures are nearly always caused by thrombosis. The process of intimal hyperplasia (IH) begins days to weeks after surgery. Excessive IH produces VG stenosis and is an important component of atherosclerosis, a late complication of VG surgery. Whereas substantial advances in the prevention and treatment of native coronary artery disease have been achieved over the past 20 years, through the development of antiplatelet and lipid-lowering drugs and drugeluting stents, comparatively little progress has been made in improving the performance of saphenous VGs. Hence, there is a pressing need to develop new treatments to improve the durability of VGs [2] .
Among the many molecular and cellular signaling pathways that drive VG remodeling, purinergic signaling pathways play important roles [3, 4] . ADP and ATP are released from activated and damaged cells within VGs [5] . These extracellular nucleotides activate platelets, endothelial cells (ECs), vascular smooth muscle cells (SMCs), and immune cells, all of which contribute to VG pathology [6] [7] [8] . Human apyrases are a family of enzymes that hydrolyze extracellular ATP to ADP, as well as ADP to AMP, thereby inhibiting thrombotic, inflammatory and proliferative pathways mediated by binding of ATP and ADP to P2Y receptors on blood platelets and vascular wall cells [9] . In addition to catabolizing ATP and ADP, apyrases promote the formation of adenosine, which is generated from AMP by CD73. Adenosine inhibits inflammation and SMC proliferation [10, 11] , while promoting vasodilation [12] . Together, these effects of apyrases would be expected to produce beneficial effects on VGs.
Ectonucleotide tri(di)phosphohydrolase-1, also known as ecto-ADPase or CD39, is an apyrase expressed on the surfaces of vascular ECs and some leukocytes [13] . APT102 is a recombinant, soluble form of CD39L3 that consists of the extracellular domain of the protein, into which amino acid substitutions have been introduced that increase enzyme activity and plasma half-life [14] . Given the antithrombotic, antiproliferative and other potential beneficial effects of apyrase, we hypothesized that APT102 would prove useful in preventing VG disease. We tested this hypothesis in a murine model of VG surgery.
Materials and methods

Mice
C57BL/6J male mice from Envigo (Huntingdon, Cambridgeshire, UK) received normal chow (5008/LabDiet). Animal care and experimental procedures were approved by the University of Missouri Animal Care and Use Committee. A total of 129 mice were used to perform all of the experiments.
Cells
Human coronary artery SMCs were from Invitrogen (Waltham, MA, USA). Human aortic ECs were from ATCC. The passage number of SMCs and ECs was three or four.
APT102 and other reagents APT102 was expressed in CHO cells and purified to homogeneity, as previously described [14] . Protein purity was > 99% by SDS-PAGE and HPLC analyses. The endotoxin level of recombinant protein was < 1.0 EU ) were added to transwell upper chambers, which were placed in lower chamber wells containing DMEM F12 with 2.5% FBS and different combinations of ATP (10 lmol L À1 ), APT102 (100 nmol L À1 ), and vehicle control. After 6 h at 37°C, cells that migrated through pores to the lower chamber side of the porous membrane were fixed, stained with Diff-Quik stain set (Siemens, Berlin, Germany), and counted. For experiments involving adenosine, 5 9 10 3 SMCs or 1.5 9 10 4 ECs were added to transwell upper chambers in media containing adenosine (10 lmol L À1 or 100 lmol L
À1
) or an equal volume of vehicle control. In each experiment, duplicates or triplicates were performed for each set of experimental conditions, and the mean number of migrating cells was calculated.
Pharmacokinetic studies
Acute pharmacokinetic properties of APT102 were assessed by administering a single intraperitoneal injection of APT102. Before APT102 administration, and 1, 3, 6, 12, 24, 48 and 72 h thereafter, mice were placed without anesthesia or analgesia in a rodent restrainer device (Model 551-BSRR; Plas-Labs, Lansing, MI, USA). An incision was made with a sterile scalpel over the lateral tail vein, 2.5 cm proximal to the tail tip. Oozing blood (~50 lL) was collected into 3.8% sodium citrate, and platelet-poor plasma was prepared and stored at À 80°C. The plasma concentration of APT102 antigen was determined by ELISA involving capture of APT102 with rabbit anti-APT102 antibody (Invitrogen) and detection of bound APT102 with horseradish peroxidase-conjugated rabbit anti-APT102 antibody (Covance, Princeton, NJ, USA). Plasma ADPase activity was measured by passing plasma samples through buffer exchange columns (Econo-Pac 10DG; Bio-Rad, Hercules, CA, USA) equilibrated with 50 mmol L À1 Tris-HCl and 8 mmol L À1 CaCl 2 (pH 7.4), after which ADP (0.5 mmol L À1 ) was added. The reaction mixture was incubated at 37°C for 30 min, after which generation of inorganic phosphate was measured with the Malachite green dye method [15] . For antigen and activity assays, a standard curve was generated by analysis of solutions of purified APT102. Chronic pharmacokinetic properties of APT102 were assessed by administering APT102 by intraperitoneal injection every other day for 26 days, with the first injection occurring on day 0. Blood was collected, as described above, at baseline (1 h before day 0 injection) and on days 7, 14, 21, and 28.
VG surgery
VGs were created by implanting a segment of inferior vena cava (IVC) from a donor mouse into the right common carotid artery of a recipient mouse [16] . Anesthesia for surgery was performed with 93 mg kg À1 ketamine, 2 mg kg acepromazine, administered by intraperitoneal injection.
Histology
IH, percentage luminal stenosis and total vessel area were measured in perfusion-fixed VGs, as previously described [17, 18] . Vascular ECs were immunostained with anti-CD31 primary antibody (ab28364; Abcam, Cambridge, MA, USA) and Texas Red-conjugated goat anti-rabbit IgG (Vector, Burlingame, CA, USA), as previously described [19] . Cell proliferation was studied by the use of anti-proliferating cell nuclear antigen (PCNA) antibody (PC10; Santa Cruz Biotechnology, Dallas, TX, USA) and peroxidase-conjugated anti-mouse IgG (Invitrogen), as previously described [17] . For all experiments, isotype non-immune primary antibodies were used as controls, and the results confirmed the specificity of reaction conditions for the antigen of interest. Quantification of PCNApositive immunostaining was performed by analyzing four prespecified regions of interest (ROIs) within the neointima of each VG, assessed in computerized images of cross-sections of each VG by false-color segmentation analysis, as previously described [17] . Quantification of CD31-positive immunostaining was performed with similar methods, with the ROI drawn at the interface of the blood vessel wall and lumen (i.e. overlying ECs).
VG thrombosis
Mice underwent VG surgery and received APT102 (1 mg kg À1 ) or an equal volume of 0.9% NaCl by intraperitoneal injection immediately after surgery and on days 2, 4 and 6 postoperatively. On day 6, 4 h after administration of APT102 or control, mice were anesthetized. The vein graft was exposed, and a flow probe (Model 0.5 VB; Transonic Systems, Ithaca, NY, USA) interfacing with a Transonic Model T106 flowmeter and a computerized data acquisition program (Windaq; DATAQ Instruments, Akron, OH, USA) was applied to the VG. Thrombosis was induced by applying two pieces of filter paper (1 9 2 mm; Whatman No. 1001 055) saturated with 10% FeCl 3 (Fisher Scientific, Waltham, MA, USA) on the VG, one on each left lateral aspect, for 3 min. Warmed saline was placed in the wound, and VG blood flow was monitored for a maximum of 60 min. The occlusion time was defined as the time interval between initiation of FeCl 3 injury and the fall of blood flow to 0 mL min À1 for 1 min. A Carstairs stain kit (American MasterTech Scientific, Lodi, CA, USA) was used to stain thrombi in excised VGs.
Surgical bleeding
Mice received APT102 (1.0 mg kg
À1
) or TBS control by intraperitoneal injection. Four hours later, mice were anesthetized by intraperitoneal administration of ketamine, xylazine, and acepromazine, and the right carotid artery was completely exposed by incising the skin and using blunt dissection to separate tissues surrounding the artery. Sterile 0.9% NaCl (75 lL) was gently infused into the surgical site, allowed to dwell for 2 min, and aspirated, after which the saline infusion was repeated twice, for a total of three washes of the surgical field. Blood in the saline washes was quantified by measuring the A 560 nm of pooled saline samples. The operator was blinded to treatment group during surgery and while collecting saline washes.
Platelet aggregation
The mice used to study the effects of APT102 on platelet aggregation were the same as those used to quantify surgical bleeding. Immediately after collection of saline washes from the carotid artery surgical field (which was 4.5 h after administration of APT102 or control, as described in the preceding paragraph), blood was collected from the surgically exposed abdominal IVC into 3.8% sodium citrate supplemented with lepirudin (Bayer, Leverkusen, Germany; final plasma concentration 25 lg mL
À1
). Platelet-rich plasma was prepared, and ADP-induced platelet aggregation was studied by light transmission aggregometry, as previously described [20] . The operator was blinded to treatment group when collecting blood and studying platelet aggregation.
Prothrombin time (PT)
PT was determined as previously described [20] , except that mouse brain extract (prepared by homogenizing 200 mg of fresh brain tissue in 300 lL of PBS, centrifuging the suspension, [8000 9 g, 5 min], and saving the supernatant) was used instead of commercial PT reagent.
RT-PCR
Real-time RT-PCR and quantification of gene expression were performed as previously described [17] . The primers used for amplification of CD73 cDNA were GGGCGGAAGGTTCCTGTAG and GAGGAGC-CATCCAGATAGACA. 18S rRNA gene expression was simultaneously assessed as an internal control.
Statistical analyses
Results are expressed as mean AE standard error of the mean. Student's t-test, one-way ANOVA and Kaplan-Meier survival analysis (log-rank test) were used as appropriate.
Results
APT102 shows favorable pharmacokinetic properties
We studied the pharmacokinetic properties of APT102 in mice. APT102 antigen peaked in plasma 3 h after a single intraperitoneal injection, and gradually declined over a 72-h time course with an elimination-phase half-life of 36 AE 2.4 h (Fig. 1A) . Plasma ADPase activity followed a similar trajectory (Fig. 1B) . In response to every-otherday injection of APT102 for 26 days, a steady-state plasma antigen concentration of~1 lg mL À1 was achieved (Fig. 1C) , with no significant decay of plasma ADPase activity over time (Fig. 1D ).
APT102 inhibits VG thrombosis without increasing surgical bleeding
To determine whether APT102 inhibits VG thrombosis, mice underwent VG surgery and were treated with APT102 or 0.9% NaCl control, administered once every other day for 6 days. On day 6, the VG was exposed 4 h after administration of APT102 or control, and subjected to FeCl 3 injury. Within 60 min, an occlusive thrombus formed in one of seven mice (14%) treated with APT102 versus five of six controls (83%; P < 0.02; Fig. 2A ). Histologic analysis of a thrombus retrieved from a control mouse revealed that it was platelet-rich in composition (Fig. 2B) .
Inspection of the surgical field through the dissecting microscope during thrombosis and other experiments involving carotid artery surgery revealed that surgical bleeding was minor and suggested that hemostasis was not adversely affected by APT102. To confirm this observation, we performed an experiment in which mice received intraperitoneal injections of APT102 (1 mg kg À1 ) or TBS, and 4 h later underwent skin incision and tissue dissection to fully expose the carotid artery. Surgical bleeding, quantified by spectrophotometric analysis of saline rinses of the surgical wound, did not differ significantly between treatment groups (Fig. 3A) . Immediately after assessment of surgical bleeding, blood was collected from the IVC, and platelet-rich plasma was prepared. ADP-induced aggregation was normal in control mice, but was essentially completely blocked in APT102-treated mice (Fig. 3B,C) . APT102 had no discernable effect on PT (Fig. 3D) . Together, these results suggested that APT102 inhibits thrombosis in VGs by inhibiting ADPinduced platelet aggregation, while not adversely affecting hemostasis.
APT102 shows no cellular toxicity and blocks the effects of ATP on SMC and EC proliferation VG remodeling is characterized by SMC and EC proliferation [21, 22] . APT102 had no significant effect on the growth kinetics of SMCs or ECs grown in vitro under standard cell culture conditions (Fig. 4A,B) , suggesting that it was non-toxic to these cell types. ATP, which is released in response to cell necrosis and activation, regulates SMC and EC proliferation [23] [24] [25] . To determine whether APT102 can block these effects, SMCs and ECs were incubated with ATP or vehicle control in the presence or absence of APT102. ATP produced a modest, statistically significant increase in SMC proliferation after 24 h of treatment (i.e. on day 2 of culture), and this effect was completely blocked by coadministration of APT102 (Fig. 4C) . After 72 h of treatment (i.e. on day 4 of culture), there were no significant effects of ATP or APT102 on SMC proliferation (Fig. 4D) . ATP had no significant effect on EC proliferation after 24 h of treatment (Fig. 4E ). However, a delayed effect of ATP was observed, with significant inhibition of EC proliferation after 72 h of treatment, and this antiproliferative effect was significantly attenuated by coadministration of APT102 (Fig. 4F) . Together, these results suggest that APT102 in itself does not adversely affect SMC or EC proliferation, but can effectively attenuate the stimulatory effect of ATP on SMC proliferation and the inhibitory effect of ATP on EC proliferation.
APT102 inhibits SMC, but not EC, migration
SMC migration promotes neointima formation in VGs [26] , whereas EC migration is required for VG reendothelialization [27] . Incubation of ECs with APT102 alone had no significant effect on their migration ) and ATP + APT102 (10 lmol L À1 and 100 nmol L À1 , respectively) on EC proliferation, assessed after 2 days (E) and 4 days (F) of cell culture. *P < 0.05 versus control. Data are derived from quadruplicate experiments for SMCs and triplicate experiments for ECs.
© 2017 International Society on Thrombosis and Haemostasis (Fig. 5A , first white bar versus third white bar). In contrast, APT102 potently inhibited SMC migration (Fig. 5A , first black bar versus third black bar). We also studied the capacity of APT102 to block the effects of ATP on EC and SMC migration. ATP significantly increased EC migration (Fig. 5A , first white bar versus second white bar), and this effect was significantly attenuated by coadministration of APT102, restoring EC migration to a level that did not differ significantly from the negative control (Fig. 5A , first white bar versus fourth white bar). ATP also stimulated SMC migration (Fig. 5A , first black bar versus second black bar). However, coadministration of ATP and APT102 inhibited SMC migration to a level that was significantly less than that of the negative control (Fig. 5A , first black bar versus fourth black bar) and without a significant difference from that of SMCs treated with APT102 alone (Fig. 5A , third black bar versus fourth black bar). Together, these results suggest that APT102 inhibits SMC migration to a significantly greater extent than EC migration, and that this effect is not explained simply by scavenging of ATP.
Adenosine inhibits SMC, but not EC, migration
SMCs and ECs express CD73 [28, 29] , which converts AMP generated by CD39 to adenosine. Therefore, we performed experiments to examine the effects of adenosine on SMC and EC migration, reasoning that APT102 might regulate their migration not only by degrading ATP, but also by promoting adenosine formation. Adenosine inhibited SMC migration (Fig. 6A ), but not EC migration (Fig. 6B) . RT-PCR analysis demonstrated that SMCs and ECs express CD73 mRNA in similar amounts (Fig. 6C,D) , providing a basis for adenosine formation in the experiments described above involving the addition of APT102 to cells, and suggesting a potential role for adenosine in the capacity of APT102 to inhibit SMC migration to a significantly greater extent than EC migration.
APT102 inhibits VG IH
To examine the in vivo effects of APT102 on VG remodeling, mice were subjected to VG surgery, after which they received APT102 (1 mg kg À1 ) or equal volumes of 0.9% NaCl, as a control, administered by intraperitoneal injection every other day for 14 days. VGs were harvested on day 28 day after surgery. The mean intima thickness was significantly less in VGs of APT102-treated mice than in controls (Fig. 7A-D) . To exclude the small possibility that the minor differences in diluents between the APT102 and control group (i.e. TBS and 0.9% NaCl, respectively) may have affected the results, and to determine the effects of a higher dose of APT102 on IH, we repeated the experiment, administering APT102 with the same frequency and duration as before (at doses of 1-2 mg kg À1 ), with control mice receiving TBS injections. As in our initial experiment, APT102 significantly inhibited neointima formation, with no statistically significant difference in effect being seen between the doses of 1 mg kg À1 and 2 mg kg À1 (Fig. 7E-H) .
APT102 inhibits neointima cell proliferation in VGs without delaying re-endothelialization
Consistent with our morphometric analysis of neointima formation, PCNA-positive immunostaining, a marker of cell proliferation, was significantly less in VGs 28 days after surgery in APT102-treated mice than in controls (Fig. 8A) . We also performed CD31 immunostaining of VGs to study the effect of APT102 on recovery of an intact endothelium after surgery, which is an adaptive process in early VG remodeling [30] . There was no evidence of a delay of EC recovery in APT102-treated mice as compared with controls (Fig. 8B) . Together, these results suggested that APT102 inhibits cell proliferation within the wall of VGs without inhibiting re-endothelialization.
Discussion
Thrombosis, mediated by platelet deposition and activation of the blood coagulation system in response to tissue injury, inflammation, and EC denudation, is a major threat to VGs early after surgery. In addition, IH is a key early step in the remodeling response of VGs, which, when excessive, obstructs blood flow and produces ischemia. Currently, antiplatelet therapy, consisting of aspirin, either alone or in combination with a thienopyridine, is used to reduce VG thrombosis [1, 2] . Statins are the only drugs that have been shown to decrease VG IH [31, 32] . New therapies are needed to inhibit thrombosis and IH in VGs. Herein, we show that APT102, a soluble form of recombinant human apyrase, effectively inhibits both thrombosis and IH in murine VGs early after surgery. APT102 showed a favorable pharmacologic profile, with an elimination half-life of~36 h and no significant attenuation of plasma ADPase activity during repetitive administration over several weeks. Our results suggest that APT102 inhibits VG thrombosis by blocking ADPinduced aggregation. It is of note that a dose of APT102 that was sufficient to completely block ADP-induced aggregation and markedly decrease thrombosis did not increase bleeding during surgical exposure of the carotid artery, suggesting that APT102 has the potential to inhibit thrombosis without compromising hemostasis. These results are consistent with previous studies [14, 33] , and support the approach of degrading ADP, rather than blocking its receptor, P2Y 12 , as an antithrombotic strategy. Furthermore, APT102 inhibited VG IH without inhibiting re-endothelialization, which would be expected to reduce thrombotic risk as compared with other antiproliferative strategies associated with impairment of EC recovery, such as drug-eluting stents. Overall, our results suggest that APT102 has considerable promise as a therapeutic strategy to prevent both thrombosis and IH within VG thrombosis in the early postoperative period.
Several studies have examined the effects of ATP and other nucleotides on the proliferation and migration of SMCs and ECs [23] [24] [25] [34] [35] [36] [37] . Our data indicate that APT102 significantly attenuates ATP's proliferative effect on SMCs and antiproliferative effect on ECs, which together would be expected to have therapeutic value by reducing SMC proliferation and neointima formation, while blocking the negative effects of ATP on re-endothelialization. An interesting finding of our in vitro experiments is the potent inhibitory effect of APT102 on SMC, but not EC, migration. This did not appear to be a cytotoxic effect, as treatment of SMCs with APT102 alone did not inhibit proliferation. Also, APT102's antimigratory effect on SMCs did not appear to be mediated by degradation of ATP, as APT102 more than negated the increase in SMC migration induced by treating cells with ATP alone. In contrast, treatment of ECs with both ATP and APT102 restored cell migration to a level close to that of untreated controls, consistent with APT102's effect on EC migration being mediated by catabolism of ATP. Given that APT102 promotes the formation of AMP, which is converted to adenosine by CD73 [8] , we reasoned that the effects of APT102 on cell migration can be mediated not only by degradation of ATP and other nucleotides, but also by formation of adenosine. Our data suggest that adenosine inhibits SMC migration, which is consistent with a previous study [11] . However, adenosine did not inhibit EC migration. We hypothesize that the differential effects of adenosine on SMC and EC migration explain, at least in part, the capacity of APT102 to inhibit SMC migration to a significantly greater extent than EC migration. Overall, our data suggest that APT102 significantly attenuates SMC migration, a key process in the pathogenesis of IH, while having a much less pronounced effect on EC migration, and potentially even enhancing EC proliferation, particularly in microenvironments with elevated ATP concentrations, as can occur in VGs postoperatively, mediated by cell activation and death [1] . Consistent with our in vitro results, APT102 inhibited VG neointima formation without significantly attenuating re-endothelialization. Drosopoulos et al. reported that soluble human CD39 inhibited IH in injured femoral arteries of male mice, and that this was accompanied by reduced mural platelet deposition [38] . Our data suggest that the beneficial effects of soluble CD39 on IH also extend to VG remodeling, which involves distinct molecular and cellular pathways from those involved in arterial remodeling. Our study also shows that soluble CD39 exerts a highly potent antithrombotic effect, which is sufficient not only to inhibit platelet deposition on injured vascular surfaces, but also to effectively inhibit the formation of completely occlusive thrombi. Imai et al. showed that adenovirus-mediated expression of human CD39 inhibited platelet deposition and inflammation in xenografts [39] . These findings are relevant to VG pathologies, which are also inflammation-dependent [40] , and further support the use of recombinant CD39 to prevent VG disease. We used male mice in our experiments because they are larger than females, consistent with the original description of this model [16] . Although coronary and other arterial bypass surgeries are performed significantly more in men than in women, the lack of female mice is a limitation of our experiments. We consider it unlikely that the effects of APT102 on thrombosis and VG remodeling would differ significantly between male and female mice; however, we cannot exclude this possibility, which should be addressed in future studies. In summary, we have shown that APT102, a recombinant soluble form of human CD39L3, provides a dual therapeutic benefit by effectively inhibiting thrombosis and IH early after VG surgery, without any evidence of hemorrhagic effects or other side-effects, and without delaying re-endothelialization. Hence, APT102 may represent a new approach to target multiple pathways that promote VG failure. As an enzyme, APT102 requires intravenous or subcutaneous administration, which is feasible in the initial weeks to months following surgery, and could be facilitated by further modifications that prolong the compound's plasma half-life. Our data support the performance of future experiments to determine whether APT102 inhibits more advanced, obstructive VG remodeling, including in the presence of common metabolic disturbances, such as diabetes mellitus and hyperlipidemia.
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